
WHAT IS CLAIMED IS:


1. Use of a combination of compounds in the manufacture of a medicament for treating a disease or condition, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

the Compound (A) has the structure:



(A); and

the Compound (B) has the structure




(B)


wherein:


R^{1a} is selected from the group consisting of hydrogen, halogen and a substituted or unsubstituted C_1-C_6 alkyl;

Ring A-a is selected from the group consisting of a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered monocyclic heteroaryl;

Ring B-a is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl and a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl;

R^{2a} is selected from the group consisting of 

, 

and 

;

m-a is 0, 1, 2 or 3;

R^{3a} is selected from the group consisting of halogen and a substituted or unsubstituted C_1-C_6 alkyl;

X-a is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, a substituted or unsubstituted 4-6 membered monocyclic heterocyclyl, a substituted or unsubstituted amine(C_1-C_6 alkyl), a substituted or unsubstituted –NH-$(CH_2)_{1-6}$-amine, a mono-substituted amine, a di-substituted amine, an amino, a substituted or unsubstituted C_1-C_6 alkyl, a substituted or unsubstituted C_1-C_6 alkoxy, a substituted or unsubstituted C_3-C_6 cycloalkoxy, a substituted or unsubstituted (C_1-C_6 alkyl)acyl, a substituted or unsubstituted C-amido, a substituted or unsubstituted N-amido, a substituted or unsubstituted C-carboxy, a substituted or unsubstituted O-carboxy, a substituted or unsubstituted O-carbamyl and a substituted or unsubstituted N-carbamyl;

Y-a is CH or N;

Y^{1-a} is CR^{4A-a} or N;

Y^{2-a} is CR^{4B-a} or N;


Ring C-a is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl, a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl and a substituted or unsubstituted 7-10 membered bicyclic heterocyclyl;

R^{4A-a} and R^{4B-a} are independently selected from the group consisting of hydrogen, halogen and an unsubstituted C_{1-4} alkyl; and


R^{5-a} is a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl; and

wherein Compound (A), or a pharmaceutically acceptable salt thereof, and Compound (B), or a pharmaceutically acceptable salt thereof, are provided in a single pharmaceutical composition or separate pharmaceutical compositions.

2. The use of Claim 1, wherein the compound (B) is



, or a pharmaceutically acceptable salt thereof.

3. The use of Claim 1, wherein the compound (B) is , or a pharmaceutically acceptable salt thereof.

4. The use of any one of Claims 1-3, wherein the disease or condition is selected from the group consisting of a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer , a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin’s lymphoma.

5. The use of Claim 4, wherein the disease or condition is a breast cancer.

6. The use of Claim 5, wherein the breast cancer does not include any point mutations ER mutations.

7. The use of any one of Claims 4-6, wherein the breast cancer is ER positive breast cancer.

8. The use of any one of Claims 4-6, wherein the breast cancer is ER positive/HER2-negative breast cancer.

9. The use of any one of Claims 4-8, wherein the breast cancer has been previously treated with an endocrine therapy.

10. The use of Claim 9, wherein the treatment was with a selective ER modulator (SERM).

11. The use of Claim 9, wherein the treatment was with a selective ER degrader (SERD).

12. The use of Claim 9, wherein the treatment was with an aromatase inhibitor.

13. The use of Claim 12, wherein the aromatase inhibitor is a steroidal aromatase inhibitor.

14. The use of Claim 12, wherein the aromatase inhibitor is a non-steroidal aromatase inhibitor.

15. The use of any one of Claims 4-8, wherein the breast cancer has not been previously treated.

16. The use of any one of Claim 4-15, wherein the breast cancer is present in a woman.

17. The use of Claim 16, wherein the subject is a premenopausal woman.

18. The use of Claim 16, wherein the subject is a perimenopausal woman.

19. The use of Claim 16, wherein the subject is a menopausal woman.

20. The use of Claim 16, wherein the breast cancer is present in a postmenopausal woman.